You just read:

Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer

News provided by

Syndax Pharmaceuticals, Inc.

Apr 09, 2012, 08:30 ET